Wedbush Securities Inc. Has $43,000 Stake in Proteon Therapeutics Inc (NASDAQ:PRTO)

Wedbush Securities Inc. raised its holdings in Proteon Therapeutics Inc (NASDAQ:PRTO) by 76.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 104,000 shares of the biopharmaceutical company’s stock after acquiring an additional 45,000 shares during the period. Wedbush Securities Inc.’s holdings in Proteon Therapeutics were worth $43,000 as of its most recent filing with the Securities and Exchange Commission.

PRTO stock opened at $0.32 on Wednesday. The stock has a market capitalization of $5.50 million, a P/E ratio of -0.28 and a beta of 0.42. The business has a 50-day moving average of $0.38 and a 200-day moving average of $1.16. Proteon Therapeutics Inc has a fifty-two week low of $0.27 and a fifty-two week high of $3.94.

Proteon Therapeutics (NASDAQ:PRTO) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.21). As a group, sell-side analysts anticipate that Proteon Therapeutics Inc will post -0.59 earnings per share for the current fiscal year.

PRTO has been the subject of a number of research analyst reports. Zacks Investment Research cut Proteon Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Cowen reissued a “hold” rating on shares of Proteon Therapeutics in a research note on Wednesday, May 8th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $2.63.

About Proteon Therapeutics

Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes.

Featured Story: Intrinsic Value

Want to see what other hedge funds are holding PRTO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Proteon Therapeutics Inc (NASDAQ:PRTO).

Institutional Ownership by Quarter for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.